How were Botanix Pharmaceuticals' earnings last quarter?

Botanix Pharmaceuticals Limited (ASX:BOT) released its quarterly earnings results on Thursday, February, 28th. The company reported ($0.01) earnings per share for the quarter.

What other stocks do shareholders of Botanix Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Botanix Pharmaceuticals investors own include Byron Energy (BYE) , Harmony Gold Mining (HMY) , Puhui Wealth Investment Management (PHCF) , NIKE (NKE) , Michael Hill International (MHJ) , Lynas Rare Earths (LYC) , Cobalt 27 Capital (KBLT) , Eclipx Group (ECX) and Bod Australia (BDA) .

ASX:BOT

Botanix Pharmaceuticals (BOT) Stock Price, News & Analysis

→ A new way to collect income from stocks (From DTI) (Ad)

Free BOT Stock Alerts

Compare

Today's Range: N/A
50-Day Range: N/A
52-Week Range: N/A

Volume: 1.63 million shs
Average Volume: N/A
Market Capitalization: N/A

P/E Ratio: N/A
Dividend Yield: 2.96%
Price Target: N/A

Stock Analysis

Get Botanix Pharmaceuticals alerts:

Ad Tips4Traders

Uncover this 2024 Hidden Gem

Exclusive Report: Uncover a Hidden Investment Gem We’re excited to share a special report on one exceptional, publicly traded company. This company has achieved a remarkable 22+% just this year, outperforming the market and revealing the potential for significant gains.

[Click here to subscribe] and elevate your trading today.

About Botanix Pharmaceuticals Stock (ASX:BOT)

Botanix Pharmaceuticals Limited engages in the research and development of dermatology and antimicrobial products in Australia. The company engages in development of novel treatments for common skin diseases and infections. Its product pipeline includes Sofpironium Bromide, a drug in development for the treatment of primary axillary hyperhidrosis that has completed Phase 3 clinical programs; BTX 1503, a transdermal gel formulation for the treatment of serious acne in adults and teenagers that has completed Phase II clinical trials; BTX 1801, which has completed Phase IIb clinical trials for the treatment of staphylococcus aureus and methicillin resistant staphylococcus aureus; BTX 1702 that is in Phase II clinical trials for the treatment of papulopustular rosacea; and BTX 1204A for the treatment of atopic dermatitis. Botanix Pharmaceuticals Limited was incorporated in 1984 and is based in Leederville, Australia.

Ad Tips4Traders

Uncover this 2024 Hidden Gem

[Click here to subscribe] and elevate your trading today.

BOT Stock News Headlines

March 8, 2024 | wsj.com

Botanix Pharmaceuticals Ltd.

January 23, 2024 | investing.com

Botanix Pharmaceuticals Ltd (BOT)

April 18, 2024 | DTI (Ad)

A new way to collect income from stocks

Most people think of BUYING options when they talk about options. It’s how speculators leverage large sums of money hoping that a stock moves in the “right” direction over a certain period of time. The problem is - they don’t always pay off when you buy them. In fact, a contributing writer at the Financial Post studied options extensively…

January 23, 2024 | fool.com.au

If you'd put $40,000 in this ASX healthcare stock at the start of 2023, you'd have $128,000 now

December 14, 2023 | morningstar.com

Botanix Pharmaceuticals Ltd BOT

October 12, 2023 | finance.yahoo.com

Botanix Pharmaceuticals (ASX:BOT) shareholders have earned a 138% return over the last year

September 26, 2023 | fool.com.au

Guess which ASX cannabis share is crashing 36% following an FDA blow

September 20, 2023 | fool.com.au

This ASX cannabis stock is up 160% since June, and it has an FDA ruling coming up!

April 18, 2024 | Tips4Traders (Ad)

Uncover this 2024 Hidden Gem

September 1, 2023 | finance.yahoo.com

Botanix Pharmaceuticals Full Year 2023 Earnings: AU$0.008 loss per share (vs AU$0.014 loss in FY 2022)

August 12, 2023 | finanznachrichten.de

Fresh Tracks Therapeutics, Inc.: Fresh Tracks Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update

July 24, 2023 | benzinga.com

What's Happening With Fresh Tracks Therapeutics (FRTX) Shares

July 21, 2023 | benzinga.com

Why Fresh Tracks Therapeutics (FRTX) Shares Are Skyrocketing

June 30, 2023 | finance.yahoo.com

BOT.AX - Botanix Pharmaceuticals Limited

May 10, 2023 | technews.tmcnet.com

Fresh Tracks Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update

March 31, 2023 | finanznachrichten.de

Fresh Tracks Therapeutics, Inc.: Fresh Tracks Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update

February 20, 2023 | finance.yahoo.com

Botanix Pharmaceuticals (ASX:BOT) adds AU$12m to market cap in the past 7 days, though investors from five years ago are still down 47%

December 1, 2022 | finance.yahoo.com

We're A Little Worried About Botanix Pharmaceuticals' (ASX:BOT) Cash Burn Rate

November 11, 2022 | ca.finance.yahoo.com

Fresh Tracks Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate Update

October 14, 2022 | fool.com.au

Investing in ASX cannabis shares

October 14, 2022 | seekingalpha.com

RVLP RVL Pharmaceuticals plc

September 13, 2022 | finance.yahoo.com

The past three years for Botanix Pharmaceuticals (ASX:BOT) investors has not been profitable

August 31, 2022 | afr.com

Botanix Pharmaceuticals raising for its sweating treatment

August 11, 2022 | finance.yahoo.com

Eczema Clinical Trial Pipeline Insights | DelveInsight

August 11, 2022 | finance.yahoo.com

Brickell Biotech Reports Second Quarter 2022 Financial Results and Provides Corporate Update

August 10, 2022 | reuters.com

Botanix Pharmaceuticals Ltd

July 23, 2022 | fool.com.au

Why Botanix Pharmaceuticals Ltd shares rocketed 61% higher today

See More Headlines

Receive BOT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Botanix Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 2/28/2019
Today: 4/17/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: ASX
Sector: Medical
Industry: Biotechnology
Sub-Industry: N/A
Current Symbol: ASX:BOT
CUSIP: N/A
CIK: N/A
Web: www.botanixpharma.com
Phone: +61-8-94820580
Fax: N/A
Employees: 11
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): A($0.01)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-10,020,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -32.25%
Return on Assets: -18.33%

Debt

Debt-to-Equity Ratio: 0.19
Current Ratio: 9.50
Quick Ratio: 1.26

Sales & Book Value

Annual Sales: $3.77 million
Price / Sales: 0.00
Cash Flow: N/A
Price / Cash Flow: 1.50
Book Value: A$0.03 per share
Price / Book: N/A

Miscellaneous

Outstanding Shares: 1,580,000,000
Free Float: N/A
Market Cap: N/A
Optionable: Not Optionable
Beta: 1.78

The Next 7 Blockbuster Stocks for Growth Investors

Wondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.

Get This Free Report

Key Executives

Mr. Vincent P. Ippolito (Age 65)
MD & Executive Chairman
Comp: $364.85k
Dr. Howie McKibbon
Chief Executive Officer
Mr. Matthew Callahan L.L.B. (Age 51)
M.B.A., MBA LLB, Executive Director
Comp: $385.52k
Dr. Jack Hoblitzell Ph.D.
Senior Vice President of Pharmaceutical Development
Dr. Patricia S. Walker M.D. (Age 65)
Ph.D., Chief Medical Adviser
Ms. Susan Patricia Park A.C.A. (Age 49)
A.C.I.S., ACSA, AGIA, B.Com., F Fin, FCIS, Company Secretary

Key Competitors

View All Competitors

Insiders

Vince Ippolito
Sold 2,000,000 shares
Total: $170,000.00 ($0.09/share)

BOT Stock Analysis - Frequently Asked Questions

How were Botanix Pharmaceuticals' earnings last quarter?: Botanix Pharmaceuticals Limited (ASX:BOT) released its quarterly earnings results on Thursday, February, 28th. The company reported ($0.01) earnings per share for the quarter.
What other stocks do shareholders of Botanix Pharmaceuticals own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Botanix Pharmaceuticals investors own include Byron Energy (BYE), Harmony Gold Mining (HMY), Puhui Wealth Investment Management (PHCF), NIKE (NKE), Michael Hill International (MHJ), Lynas Rare Earths (LYC), Cobalt 27 Capital (KBLT), Eclipx Group (ECX) and Bod Australia (BDA).

This page (ASX:BOT) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Botanix Pharmaceuticals (BOT) Stock Price, News & Analysis

About Botanix Pharmaceuticals Stock (ASX:BOT)

BOT Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders

BOT Stock Analysis - Frequently Asked Questions

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info